Teva Slips as It Bids for BioXcel Asset in Court Sale

Teva Pharmaceuticals International GmbH, a unit of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), has bid for BioXcel Therapeutics' dexmedetomidine sublingual film through a court-supervised sale process; Teva traded at $37.10, down 1.38%, while BioXcel fell 74.65% to $0.18 as of 14:21 GMT on Aug. 28, 2026.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is trying to buy a late-stage psychiatry asset out of a courtroom rather than a boardroom. Its subsidiary, Teva Pharmaceuticals International GmbH, said it has submitted a bid for BioXcel Therapeutics, Inc.'s dexmedetomidine sublingual film — a thin, dissolvable film placed under the tongue — through a court-supervised sale process.

The product is under review at the U.S. Food and Drug Administration for at-home use in the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. If cleared, it would be the first FDA-approved at-home treatment for that condition, according to the announcement reported by Baystreet.

Markets read the two sides of the transaction very differently. As of the last trade at 14:21 GMT on Aug. 28, 2026, Teva changed hands at $37.10, down 1.38% from the prior close of $37.62, inside a day range of $36.97 to $37.42. BioXcel was quoted at $0.18, down 74.65% from $0.72, with a session range of $0.17 to $0.30.

What a court-supervised sale signals about the price

The phrase doing the heavy lifting here is "court-supervised sale process." Assets change hands that way when a seller is in an insolvency or restructuring proceeding and a judge, not the board alone, sanctions the outcome. Such processes are typically run to maximise recovery for creditors, which means bids are usually open to competing offers and a stalking-horse bidder can be topped by a rival before the sale is approved.

Two practical consequences follow. First, an acquirer buying in this setting is generally buying an asset, not a whole company, and often on terms that leave legacy liabilities behind — a structure that tends to favour the buyer on price. Second, for the selling company's shareholders, equity sits at the bottom of the queue. That ordering is the most plausible explanation for the scale of the move in BioXcel stock: a sale of the lead programme through a court process implies that whatever value is realised is destined largely for creditors, not common holders.

Teva has not disclosed a purchase price in the material announced, and no closing date has been given. Because the sale is court-supervised, completion depends on the process itself, not solely on the two parties.

Why Teva shares did not rally

A cheap shot at a potential first-in-class product would ordinarily be welcomed. Teva's decline of 1.38% on the day is modest, but it is a decline, and it came while the broad tape was flat to marginally higher — the S&P 500 proxy SPY was at $771.69, up 0.08%, the Dow tracker DIA at $535.86, up 0.12%, with the Nasdaq 100 fund QQQ down 0.21% at $719.60.

Several things sit behind that muted reception. The asset is still under FDA review, so its commercial value is contingent on an approval that has not happened. A regulatory decision on an at-home indication for acute agitation involves a sedating drug being used without a clinician present, which is exactly the kind of question that invites labelling restrictions or risk-management requirements. Investors pricing that risk will discount the revenue heavily.

There is also the shape of the deal itself. Bidding in a court process means no certainty of winning, potential for an auction that lifts the price, and a period of management attention devoted to a transaction that may not close. And for a large generics-and-branded pharmaceutical group carrying a substantial debt load, any incremental spending on early-commercial-stage assets is scrutinised for how it competes with deleveraging.

Where this fits Teva's neuroscience push

Teva framed the bid as part of its stated "Pivot to Growth" strategy. "Business development plays a critical role in accelerating our Pivot to Growth strategy," said Evan Lippman, Executive Vice President, Business Development at Teva, describing the opportunity as strengthening the company's neuroscience portfolio and reflecting a disciplined approach to assets with a clear strategic fit and attractive long-term growth.

The strategic logic is straightforward. Teva already sells into psychiatry and neurology, so a sublingual film for acute agitation would slot into an existing commercial and medical-affairs footprint rather than requiring a new one. Acute agitation in schizophrenia and bipolar disorder is currently managed largely in clinical settings; a product a patient or caregiver could use at home changes where treatment happens, which is the sort of shift that can build a market rather than divide an existing one.

That is also the reason a court sale is attractive to a buyer with distribution already in place. The value of the asset to Teva rests on infrastructure Teva already owns, not on what BioXcel could have built alone.

What to watch from here

• Competing bids. Court processes invite them. A rival bidder for the film would tell you what the market thinks the programme is worth and could push Teva's cost up or out.
• Court approval and timing. Until a judge signs off, there is no deal. Teva has not stated when it expects a decision.
• The FDA review. The economics turn on approval for at-home use and on the conditions attached to any label.
• Terms, when disclosed. Whether the consideration is cash up front or weighted toward regulatory and sales milestones will show how much risk Teva is willing to carry before approval.
• BioXcel's capital structure. Where sale proceeds land in the creditor waterfall determines whether the equity has any residual claim at all.

Reading the two share prices together

The pairing is instructive. One stock fell fractionally on news it was buying something potentially first-in-class; the other fell close to three-quarters of its value on news that a large, well-capitalised buyer wants its lead programme. That asymmetry is the market's summary of the situation: the asset may well have a future, but the vehicle that developed it is being resolved through a court, and equity holders are not the constituency the process is designed to protect.

For Teva shareholders, the near-term read is that this is a small, optional, contingent addition — not a re-rating event. The company's own framing, disciplined pursuit of assets with strategic fit, points the same way. Whether it becomes material depends on a regulator, a judge, and whoever else shows up to bid.

Key facts

• Teva (NYSE: TEVA): $37.10, -1.38%, as of 14:21 GMT Aug. 28, 2026
• BioXcel Therapeutics (BTAI): $0.18, -74.65% from prior close of $0.72
• Asset sought: Dexmedetomidine sublingual film, under FDA review for at-home use
• Process: Court-supervised sale; no price or closing date disclosed

Frequently asked questions

What exactly is Teva bidding for?

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd., has bid for BioXcel Therapeutics' dexmedetomidine sublingual film — a dissolvable film placed under the tongue. It is under FDA review for at-home use in the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, and would be a single-asset acquisition rather than a purchase of the whole company.

Why did BioXcel stock fall almost 75%?

BioXcel traded at $0.18 as of 14:21 GMT on Aug. 28, 2026, down 74.65% from a prior close of $0.72. The lead programme is being sold through a court-supervised process, which typically means proceeds are directed to creditors ahead of shareholders. Common equity ranks last in such proceedings, so a sale of the main asset can leave little or nothing for holders.

How did Teva shares react?

Teva was quoted at $37.10 as of 14:21 GMT on Aug. 28, 2026, down 1.38% from the previous close of $37.62, with a day range of $36.97 to $37.42. That decline came while broad benchmarks were roughly flat, with the S&P 500 tracker up 0.08% and the Dow tracker up 0.12%.

What is a court-supervised sale process?

It is a sale of assets conducted under the oversight of a court, usually as part of an insolvency or restructuring. A judge must approve the outcome, competing bidders can normally come forward, and the process is run to maximise recoveries for creditors. Buyers often acquire assets free of certain legacy liabilities, which tends to work in the buyer's favour on price.

Has a purchase price been announced?

No. Teva disclosed that it has made a bid but did not state consideration, structure or an expected closing date. Because the transaction runs through a court process, completion is not solely in the hands of the two companies and could be affected by competing offers or court approval requirements.

What would FDA approval mean for the product?

If the FDA clears the dexmedetomidine sublingual film for at-home use, it would be the first approved at-home treatment for acute agitation associated with schizophrenia or bipolar I or II disorder in adults. That would shift treatment of these episodes out of clinical settings. The review is ongoing and no approval decision has been announced.

Sources

• Teva Sinks on Bid to Buy BioXcel — Baystreet

Photo: cottonbro studio · Pexels Licence — source